BI 1569912
BI 1569912 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
A Study to Test Different Doses of BI 1569912 in People With Depression
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
Clinical Trials (7)
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
A Study to Test Different Doses of BI 1569912 in People With Depression
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7